Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Core Insights - Zentalis Pharmaceuticals is advancing the late-stage clinical development of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with topline data from the DENALI Phase 2 trial expected by the end of 2026, potentially supporting accelerated approval [1][2][5] - The company reported a cash position of $303.4 million as of June 30, 2025, which is projected to fund operations into late 2027 [1][5][16] Business Updates - The DENALI Phase 2 trial is ongoing, with Part 2a enrolling approximately 30 patients at two dose levels, and Part 2b designed to enroll around 70 patients based on Part 2a results [5][8] - Azenosertib is being evaluated as a monotherapy and in combination studies across multiple tumor types, demonstrating potential as a first-in-class WEE1 inhibitor [7][9] Financial Results - Research and development expenses for Q2 2025 were $27.6 million, a decrease from $48.4 million in Q2 2024, primarily due to reduced clinical and lab service costs [4][6] - General and administrative expenses for Q2 2025 were $8.4 million, down from $16.7 million in Q2 2024, reflecting a decrease in personnel and consulting expenses [4][6] - Total operating expenses for Q2 2025 were $36.1 million, compared to $65.1 million in Q2 2024 [6][14]